Over 50% of medical marijuana users were shown to experience clusters of withdrawal symptoms when they were between uses in a new, detailed study In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.
Using CBD oil for pain management? Watch out for withdrawal
Over 50% of medical marijuana users were shown to experience clusters of withdrawal symptoms when they were between uses in a new, detailed study
/health/wellness/using-cbd-oil-for-pain-management-watch-out-for-withdrawal-111610169758475.html 111610169758475 story
Washington [US], January 9 (ANI): More than half of people who use medical marijuana products to ease pain also experience clusters of multiple withdrawal symptoms when they’re between uses, a new study finds.
About 10% of the patients taking part in the study experienced worsening changes to their sleep, mood, mental state, energy, and appetite over the next two years as they continued to use cannabis.
Many of them may not recognize that these symptoms come not from their underlying condition, but from their brain and body’s reaction to the absence of substances in the cannabis products they’re smoking, vaping, eating, or applying to their skin, says the University of Michigan Addiction Center psychologist who led the study.
When someone experiences more than a few such symptoms, it’s called cannabis withdrawal syndrome, and it can mean a higher risk of developing even more serious issues such as a cannabis use disorder.
In the new research published in the journal Addiction, a team from the U-M Medical School and the VA Ann Arbor Healthcare System reports findings from detailed surveys across two years of 527 Michigan residents. All were participating in the state’s system to certify people with certain conditions for use of medical cannabis and had non-cancer-related pain.
“Some people report experiencing significant benefits from medical cannabis, but our findings suggest a real need to increase awareness about the signs of withdrawal symptoms developing to decrease the potential downsides of cannabis use, especially among those who experience severe or worsening symptoms over time,” says Lara Coughlin, Ph.D., the addiction psychologist who led the analysis.
A long-term study in medical cannabis use
The researchers asked the patients whether they had experienced any of 15 different symptoms – ranging from trouble sleeping and nausea to irritability and aggression – when they had gone a significant time without using cannabis.
The researchers used an analytic method to empirically group the patients into those who had no symptoms or mild symptoms at the start of the study, those who had moderate symptoms (meaning they experienced multiple withdrawal symptoms), and those who had severe withdrawal issues that included most or all of the symptoms.
They then looked at how things changed over time, surveying the patients one year and two years after their first survey.
At baseline, 41% of the study participants fell into the mild symptoms group, 34% were in the moderate group and 25% were classed as severe.
Misconceptions about medical cannabis
Many people who turn to medical cannabis for pain do so because other pain relievers haven’t worked, says Coughlin, an assistant professor in the Department of Psychiatry who sees patients as part of U-M Addiction Treatment Services. They may also want to avoid long-term use of opioid pain medications because they pose a risk of misuse and other adverse health consequences.
She notes that people who experience issues related to their cannabis use for pain should talk with their health care providers about receiving other pain treatments including psychosocial treatments such as cognitive-behavioral therapy.
The perception of cannabis as “harmless” is not correct, she says. It contains substances called cannabinoids that act on the brain – and that over time can lead the brain to react when those substances are absent.
In addition to a general craving to use cannabis, withdrawal symptoms can include anxiety, sleep difficulties, decreased appetite, restlessness, depressed mood, aggression, irritability, nausea, sweating, headache, stomach pain, strange dreams, increased anger, and shakiness.
Previous research has shown that the more symptoms and greater severity of symptoms a person has, the less likely they are to be able to reduce their use of cannabis, quit using it, or stay away from it once they quit.
They may mistakenly think that the symptoms happen because of their underlying medical conditions, and may even increase the amount or frequency of their cannabis use to try to counteract the effect – leading to a cycle of increasing use and increasing withdrawal.
Coughlin says people who decide to use a cannabis product for a medical purpose should discuss the amount, route of administration, frequency, and type of cannabis product with their regular health provider. They should also familiarize themselves with the symptoms of cannabis withdrawal and tell their provider if they’re experiencing them.
Feeling the urge to use cannabis after a period without use, such as soon after waking up, can be a sign of withdrawal syndrome, she notes. So can the inability to cut back on use without experiencing craving or other symptoms of withdrawal.
Because there is no medically accepted standard for medical cannabis dosing for different conditions, patients are often faced with a wide array of cannabis products that vary in strength and route of administration. Some products could pose more risk for the development of withdrawal symptoms than others, Coughlin says.
For example, people who smoked cannabis tended to have more severe withdrawal symptoms than others, while people who vaped cannabis reported symptoms that tended to stay the same or get worse but generally did not improve, over time.
As more states legalize cannabis for medical or general use, including several states that will legalize its use based on the results of last November’s election, use is expected to grow.
More about the study
The researchers asked the patients about how they used cannabis products, how often, and how long they’d been using them, as well as about their mental and physical health, their education, and employment status.
Over time, those who had started off in the mild withdrawal symptom group were likely to stay there, but some did progress to moderate withdrawal symptoms.
People in the moderate withdrawal group were more likely to go down in symptoms than up, and by the end of the study, the number of people in the severe category had dropped to 17 percent. In all, 13 percent of the patients had gone up to the next level of symptoms by the end of the first year, and 8 percent had transitioned upward by the end of two years.
Sleep problems were the most common symptom across all three groups, and many in the mild group also reported cravings for cannabis. In the moderate group, the most common withdrawal symptoms were sleep problems, depressed mood, decreased appetite, craving, restlessness, anxiety, and irritability.
The severe withdrawal symptom group was much more likely to report all the symptoms except sweatiness. Nearly all the participants in this group reported irritability, anxiety, and sleep problems. They were also more likely to be longtime and frequent users of cannabis.
Those in the severe group were more likely to be younger and to have worse mental health. Older adults were less likely to go up in withdrawal symptom severity, while those who vaped cannabis were less likely to transition to a lower withdrawal-severity group.
The study didn’t assess nicotine use or try to distinguish between symptoms that could also be related to breakthrough pain or diagnosed/undiagnosed mental health conditions during abstinence.
Coughlin and her colleagues hope future research can explore cannabis withdrawal symptoms among medical cannabis patients further, including the impact of different attempts to abstain, different types of use and administration routes, and interaction with other physical and mental health factors. Most research on cannabis withdrawal has been in recreational users, or “snapshot” looks at medical cannabis patients at a single point in time.
Further research could help identify those most at risk of developing problems, and reduce the risk of progression to cannabis use disorder, which is when someone uses cannabis repeatedly despite major impacts on their lives and ability to function. (ANI)
Abrupt withdrawal of cannabidiol (CBD): A randomized trial
Rationale: The rationale of this study was to assess occurrence of withdrawal symptoms induced by abrupt cessation of cannabidiol (CBD) after prolonged administration in healthy volunteers.
Methods: Thirty volunteers were randomized to receive 750 mg of a plant-derived pharmaceutical formulation of highly purified CBD in oral solution (100 mg/mL; Epidiolex® in the United States and Epidyolex® in Europe) twice daily (b.i.d.) for 4 weeks (Part 1) followed by 2 weeks of 750 mg b.i.d. CBD (Part 2, Arm 1) or matched placebo (Part 2, Arm 2). All volunteers completed the Cannabis Withdrawal Scale (CWS) and the 20-item Penn Physician Withdrawal Checklist (PWC-20) on days -1, 21, 28, 31, 35, 42, and at follow-up.
Results: Median CWS and PWC-20 scores slightly decreased from Part 1 to Part 2. Median CWS scores ranged from 0.0 to 4.0 (out of a possible 190) in Arm 1 and 0.0 to 0.5 in Arm 2. Median PWC-20 scores were 0.0 (out of a possible 60) in both arms. Twenty-nine (97%) volunteers in Part 1 reported all-causality treatment-emergent adverse events (AEs); the most commonly reported was diarrhea (63%). In Part 2, Arm 1, 6 (67%) volunteers reported all-causality AEs; the most commonly reported was diarrhea (44%). In Part 2, Arm 2, 9 (75%) volunteers reported all-causality AEs; the most commonly reported was headache (58%). Nine volunteers withdrew because of AEs in Part 1; 1 withdrew in Part 2, Arm 2, because of an AE that began in Part 1. Four severe AEs were reported in Part 1; the remainder were mild or moderate. No serious AEs were reported.
Conclusion: In healthy volunteers, no evidence of withdrawal syndrome was found with abrupt discontinuation of short-term treatment with CBD.
Keywords: Cannabidiol; Cannabinoid; Drug withdrawal; Epilepsy; Seizure.
Copyright © 2020 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest All authors met the International Committee of Medical Journal Editors authorship criteria. Neither honoraria nor payments were made for authorship. Lesley Taylor was an employee of GW Research Ltd. at the time the work was completed. Julie Crockett is an employee of GW Research Ltd. and has share options in the company. Bola Tayo is an employee of GW Research Ltd. and owns shares in the company. Daniel Checketts is an employee of GW Research Ltd. Kenneth Sommerville was an employee of Greenwich Biosciences, Inc. at the time the work was completed.
Perry MS. Perry MS. Epilepsy Curr. 2019 Mar-Apr;19(2):93-95. doi: 10.1177/1535759719835671. Epilepsy Curr. 2019. PMID: 30955420 Free PMC article.
Ben-Menachem E, Gunning B, Arenas Cabrera CM, VanLandingham K, Crockett J, Critchley D, Wray L, Tayo B, Morrison G, Toledo M. Ben-Menachem E, et al. CNS Drugs. 2020 Jun;34(6):661-672. doi: 10.1007/s40263-020-00726-4. CNS Drugs. 2020. PMID: 32350749 Free PMC article. Clinical Trial.
Perkins D, Butler J, Ong K, Nguyen TH, Cox S, Francis B, Mcintosh M, Lilley B. Perkins D, et al. Eur J Drug Metab Pharmacokinet. 2020 Oct;45(5):575-586. doi: 10.1007/s13318-020-00624-6. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32409982 Free PMC article. Clinical Trial.
Franco V, Perucca E. Franco V, et al. Drugs. 2019 Sep;79(13):1435-1454. doi: 10.1007/s40265-019-01171-4. Drugs. 2019. PMID: 31372958 Review.
Martin-Santos R, Crippa JA, Batalla A, Bhattacharyya S, Atakan Z, Borgwardt S, Allen P, Seal M, Langohr K, Farré M, Zuardi AW, McGuire PK. Martin-Santos R, et al. Curr Pharm Des. 2012;18(32):4966-79. doi: 10.2174/138161212802884780. Curr Pharm Des. 2012. PMID: 22716148 Review.
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Maciuk A, Mangelsdorf I, McArdle HJ, Naska A, Pelaez C, Pentieva K, Siani A, Thies F, Tsabouri S, Vinceti M, Cubadda F, Frenzel T, Heinonen M, Marchelli R, Neuhäuser-Berthold M, Poulsen M, Prieto Maradona M, Schlatter JR, Trezza V, van Loveren H, Albert O, Dumas C, Germini A, Gelbmann W, Kass G, Kouloura E, Noriega Fernandez E, Rossi A, Knutsen HK. EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al. EFSA J. 2022 Jun 7;20(6):e07322. doi: 10.2903/j.efsa.2022.7322. eCollection 2022 Jun. EFSA J. 2022. PMID: 35686177 Free PMC article.
Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. Kirkland AE, et al. Psychiatry Res. 2022 Feb;308:114347. doi: 10.1016/j.psychres.2021.114347. Epub 2021 Dec 20. Psychiatry Res. 2022. PMID: 34952255 Review.
Connor JP, Stjepanović D, Budney AJ, Le Foll B, Hall WD. Connor JP, et al. Addiction. 2022 Jul;117(7):2075-2095. doi: 10.1111/add.15743. Epub 2022 Jan 10. Addiction. 2022. PMID: 34791767 Free PMC article. Review.
Martin EL, Strickland JC, Schlienz NJ, Munson J, Jackson H, Bonn-Miller MO, Vandrey R. Martin EL, et al. Front Psychiatry. 2021 Sep 9;12:729800. doi: 10.3389/fpsyt.2021.729800. eCollection 2021. Front Psychiatry. 2021. PMID: 34566726 Free PMC article.
Morel A, Lebard P, Dereux A, Azuar J, Questel F, Bellivier F, Marie-Claire C, Fatséas M, Vorspan F, Bloch V. Morel A, et al. Front Psychiatry. 2021 Feb 22;12:565617. doi: 10.3389/fpsyt.2021.565617. eCollection 2021. Front Psychiatry. 2021. PMID: 33692705 Free PMC article. Review.